Form 4: Veracyte Director Karin Eastham Awarded Restricted Stock Units

Veracyte, Inc. Director Karin Eastham was granted 9,321 restricted stock units, increasing her beneficial ownership to 23,228 shares.

Summary

• Karin Eastham, a Director of Veracyte, Inc. (VCYT), was awarded 9,321 restricted stock units (RSUs) on June 18, 2025.
• The RSUs were acquired at a price of $0, indicating a grant rather than a purchase.
• Following this transaction, Ms. Eastham's total beneficial ownership in Veracyte, Inc. common stock is 23,228 shares.
• The awarded RSUs are scheduled to vest in full on the first anniversary of the grant date (June 18, 2026) or immediately prior to the Company's next annual meeting of stockholders, whichever occurs earlier.
• Additionally, the restricted stock units will vest in full immediately upon a change in control of Veracyte, Inc.

Sentiment

Score: 7

Explanation: The filing indicates a routine equity grant to a director, aligning their interests with shareholders, which is generally viewed positively as a standard corporate governance practice.

Positives

• The grant of restricted stock units to a director aligns their interests with long-term shareholder value.
• Equity compensation is a standard practice that incentivizes directors to contribute to the company's sustained performance and growth.

Future Outlook

The restricted stock units granted to Director Karin Eastham are set to vest on the first anniversary of the grant date (June 18, 2026) or earlier, either immediately prior to the Company's next annual meeting of stockholders or upon a change in control of the Issuer.

Industry Context

The grant of restricted stock units to a director is a common form of equity compensation across various industries, including biotechnology and diagnostics, where Veracyte operates. This practice is widely used to align the interests of company leadership with long-term shareholder value and to retain key talent.

Related Party Transactions

• Grant of 9,321 restricted stock units to Karin Eastham, a Director of Veracyte, Inc., as part of her compensation, which constitutes a transaction with a related party.

Stakeholder Impact

• Shareholders: The equity grant to a director enhances alignment between management and shareholder interests, potentially fostering long-term value creation.
• Employees: No direct impact on employees is mentioned in this filing.
• Customers: No direct impact on customers is mentioned in this filing.
• Suppliers: No direct impact on suppliers is mentioned in this filing.
• Creditors: No direct impact on creditors is mentioned in this filing.

Next Steps

• Vesting of the 9,321 restricted stock units on June 18, 2026, or earlier upon the next annual meeting or a change in control of Veracyte, Inc.

Key Dates

Keywords

Veracyte, VCYT, SEC Form 4, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Insider Transaction, Karin Eastham